Todo and colleagues describe the development of IL-12-expressing oncolytic HSV-1 derived from the clinically validated G47Δ platform for malignant melanoma. Intratumoral treatment controls both injected and distant tumors and shows enhanced efficacy with PD-1 blockade. Favorable preclinical safety supports clinical translation and has enabled the ongoing investigator-initiated clinical trial.